Shafique Virani
CIK 1856081 · View on SEC EDGAR ↗
Insider
First SEC filing: April 15, 2021 · Latest: April 15, 2021
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
0 buys (P)
0 sells (S)
Net:
$0
+ 60 non-open-market transactions below
last 12 months, based on the transactions shown below
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
60 other filings hidden
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Jan. 16, 2024 | RXRX | S 10b5-1 | 18,000 | $10.93 | $196,740 | 136,748 Direct | -11.63% | Disposed | -68.9% (price as of 2026-08-21) |
| Dec. 15, 2023 | RXRX | S 10b5-1 | 18,000 | $9.60 | $172,800 | 136,748 Direct | -11.63% | Disposed | -64.6% (price as of 2026-08-21) |
| Nov. 15, 2023 | RXRX | S 10b5-1 | 18,000 | $6.51 | $117,180 | 140,351 Direct | -11.37% | Disposed | -47.8% (price as of 2026-08-21) |
| Oct. 16, 2023 | RXRX | S 10b5-1 | 18,000 | $6.30 | $113,400 | 140,351 Direct | -11.37% | Disposed | -46.1% (price as of 2026-08-21) |
| Sept. 15, 2023 | RXRX | S 10b5-1 | 18,000 | $8.66 | $155,880 | 140,351 Direct | -11.37% | Disposed | -60.8% (price as of 2026-08-21) |
| Aug. 15, 2023 | RXRX | S 10b5-1 | 18,000 | $9.25 | $166,500 | 140,351 Direct | -11.37% | Disposed | -63.3% (price as of 2026-08-21) |
| July 26, 2023 | RXRX | S 10b5-1 | 20,000 | $14.41 | $288,200 | 143,954 Direct | -12.20% | Disposed | -76.4% (price as of 2026-08-21) |
| July 25, 2023 | RXRX | S 10b5-1 | 20,000 | $14.30 | $286,000 | 143,954 Direct | -12.20% | Disposed | -76.3% (price as of 2026-08-21) |
| July 18, 2023 | RXRX | S 10b5-1 | 30,000 | $13.74 | $412,200 | 143,954 Direct | -17.25% | Disposed | -75.3% (price as of 2026-08-21) |
| July 17, 2023 | RXRX | S 10b5-1 | 30,000 | $11.72 | $351,600 | 143,954 Direct | -17.25% | Disposed | -71.0% (price as of 2026-08-21) |
| June 16, 2023 | RXRX | S 10b5-1 | 30,000 | $9.41 | $282,300 | 143,954 Direct | -17.25% | Disposed | -63.9% (price as of 2026-08-21) |
| June 15, 2023 | RXRX | S 10b5-1 | 30,000 | $9.67 | $290,100 | 143,954 Direct | -17.25% | Disposed | -64.9% (price as of 2026-08-21) |
| June 2, 2023 | RXRX | S 10b5-1 | 17,865 | $8.93 | $159,534 | 143,954 Direct | -11.04% | Disposed | -62.0% (price as of 2026-08-21) |
| June 1, 2023 | RXRX | S 10b5-1 | 25,000 | $8.58 | $214,500 | 161,819 Direct | -13.38% | Disposed | -60.4% (price as of 2026-08-21) |
| Feb. 16, 2023 | RXRX | S 10b5-1 | 1,768 | $8.42 | $14,887 | 187,332 Direct | -0.93% | Disposed | -59.7% (price as of 2026-08-21) |
| Feb. 15, 2023 | RXRX | S 10b5-1 | 7,486 | $8.33 | $62,358 | 189,846 Direct | -3.79% | Disposed | -59.2% (price as of 2026-08-21) |
| Jan. 17, 2023 | RXRX | S 10b5-1 | 10,000 | $9.16 | $91,600 | 73,160 Direct | -12.03% | Disposed | -62.9% (price as of 2026-08-21) |
| Dec. 15, 2022 | RXRX | S 10b5-1 | 10,000 | $8.85 | $88,500 | 78,160 Direct | -11.34% | Disposed | -61.6% (price as of 2026-08-21) |
| Nov. 15, 2022 | RXRX | S 10b5-1 | 4,941 | $11.92 | $58,897 | 83,160 Direct | -5.61% | Disposed | -71.5% (price as of 2026-08-21) |
| Nov. 15, 2022 | RXRX | S 10b5-1 | 5,059 | $12.70 | $64,249 | 88,101 Direct | -5.43% | Disposed | -73.3% (price as of 2026-08-21) |
| Oct. 14, 2022 | RXRX | S 10b5-1 | 5,000 | $10.63 | $53,150 | 88,773 Direct | -5.33% | Disposed | -68.1% (price as of 2026-08-21) |
| Oct. 14, 2022 | RXRX | S 10b5-1 | 5,000 | $11.21 | $56,050 | 93,773 Direct | -5.06% | Disposed | -69.7% (price as of 2026-08-21) |
| Sept. 15, 2022 | RXRX | S 10b5-1 | 400 | $13.97 | $5,588 | 93,773 Direct | -0.42% | Disposed | -75.7% (price as of 2026-08-21) |
| Sept. 15, 2022 | RXRX | S 10b5-1 | 9,600 | $13.34 | $128,064 | 94,173 Direct | -9.25% | Disposed | -74.6% (price as of 2026-08-21) |
| Aug. 16, 2022 | RXRX | S 10b5-1 | 30,000 | $12.61 | $378,300 | 98,773 Direct | -23.30% | Disposed | -73.1% (price as of 2026-08-21) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Jan. 16, 2024 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (18,000) | $2.22 | March 3, 2030 | 18,000 | Disposed |
| Dec. 15, 2023 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (18,000) | $2.22 | March 3, 2030 | 18,000 | Disposed |
| Nov. 15, 2023 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (18,000) | $2.22 | March 3, 2030 | 18,000 | Disposed |
| Oct. 16, 2023 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (18,000) | $2.22 | March 3, 2030 | 18,000 | Disposed |
| Sept. 15, 2023 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (18,000) | $2.22 | March 3, 2030 | 18,000 | Disposed |
| Aug. 15, 2023 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (18,000) | $2.22 | March 3, 2030 | 18,000 | Disposed |
| July 26, 2023 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (20,000) | $2.22 | March 3, 2030 | 20,000 | Disposed |
| July 25, 2023 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (20,000) | $2.22 | March 3, 2030 | 20,000 | Disposed |
| July 18, 2023 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (30,000) | $2.22 | March 3, 2030 | 30,000 | Disposed |
| July 17, 2023 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (30,000) | $2.22 | March 3, 2030 | 30,000 | Disposed |
| June 16, 2023 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (30,000) | $2.22 | March 3, 2030 | 30,000 | Disposed |
| June 15, 2023 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (30,000) | $2.22 | March 3, 2030 | 30,000 | Disposed |
| Feb. 15, 2023 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (7,486) | $2.22 | March 3, 2030 | 7,486 | Acquired |
| Feb. 1, 2023 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (212,507) | $8.55 | Feb. 1, 2033 | 212,507 | Acquired |
| Jan. 17, 2023 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (5,000) | $2.22 | March 3, 2030 | 5,000 | Disposed |
| Dec. 15, 2022 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (5,000) | $2.22 | March 3, 2030 | 5,000 | Disposed |
| Nov. 15, 2022 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (5,000) | $2.22 | March 20, 2030 | 5,000 | Disposed |
| Oct. 14, 2022 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (5,000) | $2.22 | March 20, 2030 | 5,000 | Disposed |
| Sept. 15, 2022 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (5,000) | $2.22 | March 20, 2030 | 5,000 | Disposed |
| Aug. 16, 2022 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (25,000) | $2.22 | March 20, 2030 | 25,000 | Disposed |
| Feb. 4, 2022 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (5,436) | $11.40 | Feb. 4, 2032 | 5,436 | Acquired |
| Feb. 4, 2022 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (80,450) | $11.40 | Feb. 4, 2032 | 80,450 | Acquired |
| June 2, 2021 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (45,045) | $2.22 | March 20, 2030 | 45,045 | Disposed |
| April 20, 2021 | RXRX | Stock Option (Right to Buy) | Class A Common Stock [F1] (732,000) | $2.22 | March 20, 2030 | 732,000 | Acquired |
| April 20, 2021 | RXRX | Stock Option (Right to Buy) | Common Stock [F1] (732,000) | $2.22 | March 30, 2030 | 732,000 | Disposed |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 2 holdings
Securities held when first becoming an insider, per SEC Form 3.
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
RXRX
(6)Former Chief Corporate Development Officer| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2023 | $520,417 | — | $908,463 | $1,130,537 | $208,442 | — | $36,182 | $2,804,040 |
| 2020 | $413,541 | $13,000 | — | $991,749 | $28,158 | — | $20,523 | $1,466,974 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.